SURGICAL MANAGEMENT OF SOFT TISSUE SARCOMAS

PROFESSOR ROBERT U. ASHFORD MD FRCS(TR & ORTH)

CONSULTANT ORTHOPAEDIC & MUSCULOSKELETAL TUMOUR SURGEON, LEICESTER ORTHOPAEDICS HONORARY PROFESSOR, LEICESTER CANCER RESEARCH CENTRE PRESIDENT, BRITISH ORTHOPAEDIC ONCOLOGY SOCIETY ABC FELLOW 2014

Leicester Orthopædics























DILEMMA...

- More wound complications with preop
- Lower dose
- Less long term sequelae
- So if you are going to give radiotherapy first accept wound complications

<u>10x1c</u>	<u>ity</u> .	Following limb With time (1 y >TESS >MSTS	e to pre-o b preserv (ear) sco (physical (clinical	p KT in earry ation res are simil disability), measures)	y stage lar for t Davi	s (6 wee both trea s et al JCC	tment	group	s:
		×SF-30	bodily pa	110					
2-year La	ate Com	plications (>=	grade 2) 181	Gra	de 3 or 4 subo	utaneou	s fibrosis	
	Pre-op RT	Post-op RT	p		×		_	Pre-op 87 Post-op 87 1	
Fibrosis	31.5%	48.2%	0.07	Percent there	Probability: Pre-op: Post-op	3 yr 5 yr 20% 23% 25% 35%		L	
Stiffness	17.8%	23.2%	0.51	21 A	P=0.02, log r equality	ank for of groups	6		
Edema	15.1%	23.2%	0.26)) Sis Instantin pa	N S Rectardo	ii ii Tane (Neas)	2.8%	7 7 8484	Pealt
Davis et al R	Radiother On	icol, 2005		O'Sullivan e	et al ASC	O, 2004		ela fila	he-op®)
Correlate	es with ir	ncreasing field	size an	d dose		Princess N	largare	t Hospita	

Fractures Following Radiotherapy and Limb-Salvage Surgery for Lower Extremity Soft-Tissue Sarcomas

A COMPARISON OF HIGH-DOSE AND LOW-DOSE RADIOTHERAPY

364 lower extremity EBRT alone a	at PMH (1986-98)							
Fracture rates:	Crude rates	5-yr frequency						
Overall	6.3 %	4 %						
High-dose (60-66 Gy)	10 %	7 %						
Low-dose (50 Gy, mostly pre-op)	2 %	0.6 %						
Females (6% vs. 2%, p = 0.02); >	55 yr (7% vs. 1%	o, p = 0.004)						
Age, gender, and RT independent factors								
Median fracture time: 44 months								
Holt et al. JBJS 2005		Princess Margaret Hospítal						

SURGERY Alone- It is limited by tumour accessibility, patient's medical condition, tumour's extent (D'OH!) In combination with RT ± chemo Cure or palliative goals



















